Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
November 10, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30%...
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
October 27, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second...
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
August 02, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
June 13, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 07:30 ET
|
Intra-Cellular Therapies Inc.
First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression First quarter 2022 CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the...
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
May 03, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
April 25, 2022 07:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
April 21, 2022 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...